![]() |
|
|
Vol. 289, Issue 3, 1350-1361, June 1999
Department of Psychiatry and Behavioral Sciences, Johns Hopkins
University School of Medicine, Baltimore, Maryland
The discriminative stimulus and subjective effects of opioid mixed
agonist-antagonists were assessed in volunteer nondependent heroin
users trained in a three-choice drug discrimination procedure to
discriminate among the effects of i.m. administration of 2 ml of
saline, 1 mg of hydromorphone, and 4 mg of hydromorphone (a
morphine-like µ agonist). Other subjective, behavioral, and physiological measures were concurrently collected. The discrimination was readily learned by six of the eight subjects. After training, generalization curves were determined for the following i.m. drug conditions: hydromorphone (0.375-4.0 mg), pentazocine (7.5-60 mg),
butorphanol (0.75-6 mg), nalbuphine (3-24 mg), and buprenorphine (0.075-0.6 mg). All five of the test drugs were discriminated significantly or showed trends toward being discriminated as
hydromorphone 1 mg-like at one or more dose levels.
Hydromorphone showed an inverted U-shaped dose-effect function on the
hydromorphone 1 mg-like discrimination. Subjective effect measures
produced clearer differentiation among the test drugs than did drug
discrimination performance. The present results differ from those of a
previous study that observed a close relationship between the results
of the discrimination measure and subjective effect measures. The previous study used similar methods and test drugs but different training drugs (e.g., 3 mg of hydromorphone versus 6 mg of butorphanol versus saline). It appears that both the sensitivity of drug
discrimination performance to between-drug differences and the
relationship between discriminative and subjective effects depends upon
the specific discrimination that is trained (e.g., two-choice or
three-choice). The present high dose-low dose-saline discrimination
procedure appears useful for assessing partial agonist activity. The
present data are consistent with partial agonist activity for
pentazocine, butorphanol, nalbuphine, and buprenorphine.
This article has been cited by other articles:
![]() |
T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260. [Abstract] [PDF] |
||||
![]() |
K. L. Preston and G. E. Bigelow Effects of Agonist-Antagonist Opioids in Humans Trained in a Hydromorphone/Not Hydromorphone Discrimination J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 114 - 124. [Abstract] [Full Text] |
||||